<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">V.F.Snegirev Archives of Obstetrics and Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">V.F.Snegirev Archives of Obstetrics and Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Архив акушерства и гинекологии им. В.Ф. Снегирева</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-8726</issn><issn publication-format="electronic">2687-1386</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">702019</article-id><article-id pub-id-type="doi">10.17816/aog702019</article-id><article-id pub-id-type="edn">NCFBOY</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Сlear cell (mesonephroid) carcinoma of the ovary and сlear cell renal cell carcinoma: a search for common immunohistochemical markers</article-title><trans-title-group xml:lang="ru"><trans-title>Светлоклеточный (мезонефроидный) рак яичников и светлоклеточный почечно-клеточный рак: поиск общих иммуногистохимических маркёров</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>卵巢透明细胞（中肾样）癌与肾透明细胞癌： 寻找共同免疫组化标志物</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2842-2910</contrib-id><contrib-id contrib-id-type="spin">1400-8734</contrib-id><name-alternatives><name xml:lang="en"><surname>Zholobova</surname><given-names>Maria N.</given-names></name><name xml:lang="ru"><surname>Жолобова</surname><given-names>Мария Николаевна</given-names></name><name xml:lang="zh"><surname>Zholobova</surname><given-names>Maria N.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine)</p></bio><email>zholobova_m_n@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-2694-5547</contrib-id><contrib-id contrib-id-type="spin">8998-6033</contrib-id><name-alternatives><name xml:lang="en"><surname>Skripnik</surname><given-names>Nataliia A.</given-names></name><name xml:lang="ru"><surname>Скрипник</surname><given-names>Наталия Анатольевна</given-names></name><name xml:lang="zh"><surname>Skripnik</surname><given-names>Nataliia A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>NatalieSkripnik25@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8125-1829</contrib-id><contrib-id contrib-id-type="spin">6066-9273</contrib-id><name-alternatives><name xml:lang="en"><surname>Chushkov</surname><given-names>Yury V.</given-names></name><name xml:lang="ru"><surname>Чушков</surname><given-names>Юрий Васильевич</given-names></name><name xml:lang="zh"><surname>Chushkov</surname><given-names>Yury V.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><email>chushkov_yu_v@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0834-0806</contrib-id><contrib-id contrib-id-type="spin">8404-8366</contrib-id><name-alternatives><name xml:lang="en"><surname>Berishvili</surname><given-names>Manana V.</given-names></name><name xml:lang="ru"><surname>Беришвили</surname><given-names>Манана Владимировна</given-names></name><name xml:lang="zh"><surname>Berishvili</surname><given-names>Manana V.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><email>berishvili_m_v@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6331-3109</contrib-id><contrib-id contrib-id-type="spin">4137-4848</contrib-id><name-alternatives><name xml:lang="en"><surname>Chilova</surname><given-names>Raisa A.</given-names></name><name xml:lang="ru"><surname>Чилова</surname><given-names>Раиса Алексеевна</given-names></name><name xml:lang="zh"><surname>Chilova</surname><given-names>Raisa A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><email>Сhilova_r_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6603-804X</contrib-id><contrib-id contrib-id-type="spin">3122-7420</contrib-id><name-alternatives><name xml:lang="en"><surname>Ageev</surname><given-names>Mikhail B.</given-names></name><name xml:lang="ru"><surname>Агеев</surname><given-names>Михаил Борисович</given-names></name><name xml:lang="zh"><surname>Ageev</surname><given-names>Mikhail B.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><email>ageev_m_b@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5351-0854</contrib-id><contrib-id contrib-id-type="spin">1020-0592</contrib-id><name-alternatives><name xml:lang="en"><surname>Osadchev</surname><given-names>Vasilii B.</given-names></name><name xml:lang="ru"><surname>Осадчев</surname><given-names>Василий Борисович</given-names></name><name xml:lang="zh"><surname>Osadchev</surname><given-names>Vasilii B.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine), Associate Professor</p></bio><email>Osadchy_v_b@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7557-9318</contrib-id><name-alternatives><name xml:lang="en"><surname>Tarasova</surname><given-names>Elena O.</given-names></name><name xml:lang="ru"><surname>Тарасова</surname><given-names>Елена Олеговна</given-names></name><name xml:lang="zh"><surname>Tarasova</surname><given-names>Elena O.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><bio xml:lang="zh"><p>MD</p></bio><email>tarasova8080@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff><aff><institution xml:lang="zh">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">City Clinical Hospital named after V.V. Veresaev</institution></aff><aff><institution xml:lang="ru">Городская клиническая больница им. В.В. Вересаева</institution></aff><aff><institution xml:lang="zh">City Clinical Hospital named after V.V. Veresaev</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-03-20" publication-format="electronic"><day>20</day><month>03</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-08-11" publication-format="electronic"><day>11</day><month>08</month><year>2026</year></pub-date><volume>13</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>107</fpage><lpage>117</lpage><history><date date-type="received" iso-8601-date="2026-01-31"><day>31</day><month>01</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-03-03"><day>03</day><month>03</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2026, Eco-Vector</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><copyright-holder xml:lang="zh">Eco-Vector</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-08-11"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://archivog.com/2313-8726/article/view/702019">https://archivog.com/2313-8726/article/view/702019</self-uri><abstract xml:lang="en"><p>The urinary and reproductive organs are closely related in their development. Most of them originate from the mesoderm and, in early embryogenesis, represent a single developmental process. Clear cell ovarian carcinoma and clear cell renal cell carcinoma share similar histological features and an aggressive clinical course. Ovarian cancer is the eighth most common cancer in women worldwide. Clear cell ovarian carcinoma is a rare histological subtype, accounting for approximately 5% of all ovarian tumors. Clear cell renal cell carcinoma is the most common histological subtype of kidney tumors, comprising 80%–85% of all renal neoplasms, and is more frequent in men. Based on current international and national studies, this article evaluates the diagnostic value of immunohistochemical markers including HNF1B, napsin A, IMP3, CD10, SR-B1, PAX-8, CAIX, AMACR, and Ki-67 to identify similarities and differences between these tumors and to explore the potential use of these markers in differential diagnosis, particularly in challenging clinical situations, such as the evaluation of women to rule out metastatic disease.</p></abstract><trans-abstract xml:lang="ru"><p>Мочевые и половые органы тесно связаны в своём развитии. Большинство из них является производным среднего зародышевого листка — мезодермы и на ранних этапах эмбриогенеза представляет собой единый процесс. Светлоклеточная карцинома яичников и светлоклеточный почечно-клеточный рак имеют сходную гистологическую картину и агрессивное течение. Рак яичников является восьмым наиболее распространённым злокачественным новообразованием у женщин во всём мире. Светлоклеточная карцинома яичников — редко встречающийся гистологический вариант опухолей, на долю которого приходится около 5% от всех новообразований яичников. Светлоклеточный почечно-клеточный рак является самым распространённым гистологическим вариантом опухолей данной локализации, на его долю приходится 80–85% всех новообразований почек, при этом чаще всего он встречается среди мужчин. В данной статье на основании современных международных и отечественных исследований проведена оценка диагностической ценности иммуногистохимических маркёров, а именно HNF1B, Напсина А, IMP3, CD10, SR-B1, PAX-8, CAIX, AMACR, Ki-67, с целью поиска сходства и различий между данными опухолями, а также для дальнейшей возможности использования иммуногистохимических маркёров в дифференциальной диагностике этих заболеваний, особенно в сложных клинических ситуациях — при обследовании женщин с целью исключения метастатического поражения.</p></trans-abstract><trans-abstract xml:lang="zh"><p>泌尿和生殖器官在发育过程中密切相关。两者大多源自中胚层（中胚叶），在胚胎发生的早期阶段表现为一个统一过程。卵巢透明细胞癌与肾透明细胞癌具有相似的组织学图像和侵袭性病程。卵巢癌是全球女性第八大常见恶性肿瘤。卵巢透明细胞癌是一种罕见肿瘤组织学亚型，约占所有卵巢肿瘤的5%。肾透明细胞癌是该部位最常见的组织学亚型，占所有肾脏肿瘤的80–85%，且多见于男性。本文基于当代国内外研究，对免疫组化标志物HNF1B、天冬氨酸蛋白酶A、IMP3、CD10、SR-B1、PAX-8、CAIX、AMACR、Ki-67的诊断价值进行评估，旨在寻找这两种肿瘤之间的相似性和差异性，并进一步探讨免疫组化标志物在鉴别诊断中的应用可能性，特别是在排除转移性病变的复杂临床情况下（如对女性患者的检查）。</p></trans-abstract><kwd-group xml:lang="en"><kwd>clear cell carcinoma</kwd><kwd>HNF1B</kwd><kwd>CD10</kwd><kwd>SR-B1</kwd><kwd>PAX-8</kwd><kwd>CAIX</kwd><kwd>AMACR</kwd><kwd>Ki-67</kwd><kwd>review</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>светлоклеточный рак</kwd><kwd>HNF1B</kwd><kwd>CD10</kwd><kwd>SR-B1</kwd><kwd>PAX-8</kwd><kwd>CAIX</kwd><kwd>AMACR</kwd><kwd>Ki-67</kwd><kwd>обзор</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>透明细胞癌</kwd><kwd>HNF1B</kwd><kwd>CD10</kwd><kwd>SR-B1</kwd><kwd>PAX-8</kwd><kwd>CAIX</kwd><kwd>AMACR</kwd><kwd>Ki-67</kwd><kwd>综述</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ji JX, Wang YK, Cochrane DR, Huntsman DG. Clear cell carcinomas of the ovary and kidney: clarity through genomics. J Pathol. 2018;244(5):550–564. doi: 10.1002/path.5037 EDN: YFQURV</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kuznetsov SL, Mushkambarov NN. Histology, cytology and embryology. Moscow: Meditsinskoe informatsionnoe agentstvo; 2016. 640 р. (In Russ.) ISBN: 978-5-9986-0249-8</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kaprin AD, Starinsky VV, Shakhzadova AO, editors. Malignant neoplasms in Russia in 2023 (morbidity and mortality). Moscow; 2024. 275 р. (In Russ.) ISBN: 978-5-85502-298-8</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Khalimbekova DI, Ulrikh EA. Mesonephroid (clear cell) carcinoma of the female genital tract (literature review). Siberian Journal of Oncology. 2012;(6):76–83. EDN: PLFPMV</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Rosso R, Turinetto M, Borella F, et al. Ovarian clear cell carcinoma: open questions on the management and treatment algorithm. Oncologist. 2025;30(1):oyae325. doi: 10.1093/oncolo/oyae325 EDN: IZZFUT</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ozhiganova IN. Morphology of ovarian cancer in the WHO classification of 2013. Practical Oncology. 2014;15(4):143–152. (In Russ.) EDN: TROQFN</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Rose TL, Kim WY. Renal cell carcinoma: a review. JAMA. 2024;332(12):1001–1010. doi: 10.1001/jama.2024.12848 EDN: OWBPHH</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mazurenko NN, Tsyganova IV, Strelnikov VV. Spectrum of VHL mutations in clear cell renal cell carcinoma. Advances in Molecular Oncology. 2020;7(3):48–57. doi: 10.17650/2313-805X-2020-7-3-48-57 EDN: KLAJGO</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bahadoram S, Davoodi M, Hassanzadeh S, et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022;39(3):2022-vol3</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Nassour AJ, Jain A, Hui N, et al. Relative risk of bladder and kidney cancer in Lynch syndrome: systematic review and meta-analysis. Cancers (Basel). 2023;15(2):506. doi: 10.3390/cancers15020506 EDN: YUIMAN</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hollis RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 2023;555:216057. doi: 10.1016/j.canlet.2023.216057 EDN: NBADCN</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Iida Y, Okamoto A, Hollis RL, et al. Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer. 2021;31(4):605–616. doi: 10.1136/ijgc-2020-001656 EDN: AQJTFL</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Tong A, Di X, Zhao X, Liang X. Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics. Front Genet. 2023;14:952379. doi: 10.3389/fgene.2023.952379 EDN: LWECZU</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Deng J, Tu S, Li L, et al. Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study. Cancer Rep (Hoboken). 2024;7(6):e2116. doi: 10.1002/cnr2.2116 EDN: MYGEVS</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Sánchez-Cazorla E, Carrera N, García-González MÁ. HNF1B transcription factor: key regulator in renal physiology and pathogenesis. Int J Mol Sci. 2024;25(19):10609. doi: 10.3390/ijms251910609 EDN: SWLOWW</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Nili F, Tavakoli M, Izadi Mood N, et al. Napsin-A expression, a reliable immunohistochemical marker for diagnosis of ovarian and endometrial clear cell carcinomas. Iran J Pathol. 2020;15(2):81–85. doi: 10.30699/ijp.2020.106598.2222 EDN: FUHSFF</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Wang H, Chen C, Wang D, et al. Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer. BMC Cancer. 2023;23(1):1210. doi: 10.1186/s12885-023-11641-4 EDN: LCUGRE</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Němejcová K, Bártů MK, Michálková R, et al. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors. Diagn Pathol. 2023;18(1):15. doi: 10.1186/s13000-023-01300-4 EDN: FEXRVK</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Hoffmann NE, Sheinin Y, Lohse CM, et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008;112(7):1471–1479. doi: 10.1002/cncr.23296</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Nalivaeva NN, Zhuravin IA, Turner AJ. Neprilysin expression and functions in development, ageing and disease. Mech Ageing Dev. 2020;192:111363. doi: 10.1016/j.mad.2020.111363 EDN: EQRCKJ</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Tsoi IV. The role of molecular markers in the diagnosis of renal cell carcinoma and prostate cancer [dissertation]. Moscow; 2020. 183 р. EDN: UPFVJF</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Jiang T, Diao X, Ding M, et al. SR-B1 and CD10 combined immunoprofile for differential diagnosis of metastatic clear cell renal cell carcinoma and clear cell carcinoma of the ovary. J Mol Histol. 2021;52(3):539–544. doi: 10.1007/s10735-021-09963-3 EDN: OFXQSG</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Ali ET, Mohamed NS, Shafig IR, et al. Immunohistochemical expression of PAX-8 in Sudanese patients diagnosed with malignant female reproductive tract tumors. BMC Res Notes. 2020;13(1):396. doi: 10.1186/s13104-020-05246-4 EDN: EPAYSQ</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Chaves-Moreira D, Morin PJ, Drapkin R. Unraveling the Mysteries of PAX8 in reproductive tract cancers. Cancer Res. 2021;81(4):806–810. doi: 10.1158/0008-5472.CAN-20-3173 EDN: WHXBYY</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Li L, Hossain SM, Eccles MR. The role of the PAX genes in renal cell carcinoma. Int J Mol Sci. 2024;25(12):6730. doi: 10.3390/ijms25126730 EDN: OPHSUB</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Yousef A, Kim SS, Krizova A. CAIX immunostaining in non-neoplastic renal diseases. Cancer Diagn Progn. 2022;2(6):661–667. doi: 10.21873/cdp.10157 EDN: QZFKAZ</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Choschzick M, Oosterwijk E, Müller V, et al. Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch. 2011;459(2):193–200. doi: 10.1007/s00428-011-1105-y EDN: IPLPNA</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Nili F, Fathi S, Tavakoli M, et al. Diagnostic accuracy of alpha-methylacyl-CoA racemase immunohistochemical expression for the diagnosis of ovarian and endometrial clear cell carcinomas. Iran J Pathol. 2023;18(1):57–63. doi: 10.30699/IJP.2023.556417.2925 EDN: PTABLO</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Rao BV, Regulavalasa T, Fonseca D, et al. Differentiation of renal cell tumors with morphological cocktails using a minimal panel of immunohistochemical markers. Urol Ann. 2020;12(3):236–240. doi: 10.4103/UA.UA_131_18 EDN: HCOKES</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Zhang T, Ming Y, Xu J, et al. Radiomics and Ki-67 index predict survival in clear cell renal cell carcinoma. Br J Radiol. 2023;96(1150):20230187. doi: 10.1259/bjr.20230187 EDN: HBMOZC</mixed-citation></ref></ref-list></back></article>
